Search Results

1,670 Results for "kite pharma.rss".

Sort By

Press Releases

Kite’s Next-Generation Bicistronic CAR T-Cell Therapies Show Encouraging Phase 1 Results in Relapsed/Refractory B-Cell Lymphoma in New Data at ASH 2025

December 8, 2025
·
6 min read
Press Releases

Kite Announces New Data for Pivotal iMMagine-1 Study at ASH 2025, Highlighting Anito-cel’s Opportunity in Relapsed or Refractory Multiple Myeloma

December 8, 2025
·
10 min read
Collaboration

Kite Makes $1.5B+ Cell Therapy Pact With Pregene as Others Pull Back

With more than $1.5 billion on the line, Gilead looks to bolster its CAR T portfolio.

October 17, 2025
·
2 min read
·
Tristan Manalac
Press Releases

Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025

November 3, 2025
·
19 min read
Layoffs

Appia, Former Kite Cell Therapy Collaborator, Shuts Down

Appia Bio’s shutdown continues an unfortunate trend this year that has seen biotech closures nearly every month.

August 26, 2025
·
2 min read
·
Tristan Manalac
Press Releases

Gilead and Kite Reinforce Bold Commitment to Transform Cancer Care With New Data at ESMO 2025

October 14, 2025
·
18 min read
Press Releases

Cellares Appoints Former Kite Global Ops Leader, Christopher McDonald, to Board of Advisors

September 23, 2025
·
3 min read
Layoffs

Gilead and Kite Are Cutting Employees, Closing Seattle, Philadelphia Sites

Gilead’s layoffs include 72 employees at its Seattle location, which will close. Kite will shut down its Philadelphia facility. The layoffs are attributed to aligning resources with long-term strategic goals.

November 15, 2024
·
2 min read
·
Angela Gabriel
Business

Cellares Announces Agreement with Kite to Evaluate Its Cell Shuttle Automated Manufacturing Platform

Cellares today announced that Kite , a Gilead Company, will evaluate Cellares’ automated manufacturing platform, the Cell Shuttle.

June 27, 2024
·
2 min read
Business

Encouraging New Data Presented on Kite’s Yescarta® for Relapsed/Refractory Central Nervous System Lymphoma

Kite, a Gilead Company (Nasdaq: GILD), announced data from a pilot study in collaboration with Dana-Farber Cancer Institute that demonstrate Yescarta® (axicabtagene ciloleucel) is well-tolerated in patients living with relapsed or refractory (R/R) primary or secondary central nervous system lymphoma (PCNSL and SCNSL).

June 3, 2024
·
19 min read